Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Fineline Cube Dec 16, 2025
Company Deals

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials

Fineline Cube Dec 16, 2025
Company Deals

Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option

Fineline Cube Dec 16, 2025
Company Deals

Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis

Fineline Cube Dec 16, 2025
Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025
Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Fineline Cube Dec 16, 2025
Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Fineline Cube Dec 16, 2025
Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Fineline Cube Dec 16, 2025
Drug Policy / Regulatory

CDE Releases 62nd Batch of Chemical Generic References, Updates 39 Specifications

Fineline Cube Sep 1, 2022

The Center for Drug Evaluation (CDE) has released the 62nd batch of chemical generic reference...

Company Drug

Jacobio Pharmaceuticals Doses First Patient in JAB-21822 Phase IIa Trial for KRAS G12C NSCLC

Fineline Cube Sep 1, 2022

China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a...

Company Deals

Novartis Partners with Beijing’s Changping District to Expand Drug Development

Fineline Cube Sep 1, 2022

Swiss pharma giant Novartis (NYSE: NVS) has partnered with Beijing’s Changping district government to expand...

Company

GenScript Biotech’s H1 2022 Revenue Rises 32.7% on Carvykti CAR-T Sales

Fineline Cube Sep 1, 2022

Nanjing-based GenScript Biotech, a biopharma and contract research firm, reported a 32.7% year-on-year (YOY) revenue...

Company Deals

Mayo Clinic Launches Mayflower BioVentures to Accelerate Cell and Gene Therapies

Fineline Cube Sep 1, 2022

The Mayo Clinic, a leading US hospital group, has launched Mayflower BioVentures, a cell and...

Company Deals

Biointron Raises USD 72M in Series B to Expand CRO Services and Antibody Platform

Fineline Cube Sep 1, 2022

Shanghai-based Biointron, a recombinant protein/antibody reagent contract research organization (CRO), has raised nearly RMB 500...

Company

Simcere Pharma’s H1 2022 Revenue Rises 27% on New Drug Sales, R&D Push

Fineline Cube Sep 1, 2022

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) reported RMB 2.7 billion (USD 391 million) in...

Company

Alphamab Oncology Reports H1 2022 Revenue Growth Driven by Envafolimab Commercialization

Fineline Cube Sep 1, 2022

China-based Alphamab Oncology (HKG: 9966) reported RMB 53.57 million (USD 7.7 million) in H1 2022...

Company Drug

Akeso Bio’s AK112 Wins Breakthrough Designation for First-Line NSCLC

Fineline Cube Sep 1, 2022

China’s Akeso Bio has secured a breakthrough therapy designation (BTD) from the Center for Drug...

Company

RemeGen’s H1 2022 Revenue Soars 1,094% on Aidixi, Taiai Sales

Fineline Cube Sep 1, 2022

China-based biotech RemeGen (HKG: 9995) reported RMB 349 million (USD 50.5 million) in revenue for...

Policy / Regulatory

Beijing Adjusts UEBMI Account Management, Boosting Outpatient Coverage

Fineline Cube Aug 31, 2022

The Beijing Municipal Medical Insurance Bureau has adjusted the management of Urban Employee Basic Medical...

Company

Junshi Biosciences’ H1 2022 Financials Show Tuoyi Sales Growth Despite Revenue Drop

Fineline Cube Aug 31, 2022

Shanghai-based Junshi Biosciences (HKG: 1877) reported a 55.26% year-on-year (YOY) revenue decline to RMB 946.05...

Company Drug

Connect Biopharma Completes Phase I Trial of CBP-174 for Itch in Skin Diseases

Fineline Cube Aug 31, 2022

Sino-US biotech Connect Biopharma Holdings Ltd (NASDAQ: CNTB), headquartered in San Diego, California, and Taicang,...

Company Deals

RoosterBio Taps MBL Beijing Biotech as Exclusive Distributor in China

Fineline Cube Aug 31, 2022

US-based RoosterBio Inc. has appointed MBL Beijing Biotech, a subsidiary of JSR Life Sciences Company,...

Company Drug

Boehringer, Eli Lilly’s Jardiance Wins NMPA Approval for Heart Failure with Preserved Ejection Fraction

Fineline Cube Aug 31, 2022

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

E-nitiate Biopharma Raises RMB 100M in Series A to Advance Autoimmune Disease Drugs

Fineline Cube Aug 31, 2022

China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a drug developer focused on autoimmune diseases, has raised...

Company Deals

Kangtai Bio Partners with Philippine Firm on Pneumonia Vaccines

Fineline Cube Aug 31, 2022

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has partnered with an unnamed Philippine enterprise...

Company

MicroPort Scientific Posts 10% Revenue Growth Despite COVID-19 in 2022 Interim Results

Fineline Cube Aug 31, 2022

China-based MicroPort Scientific Corp. (HKG: 0853) reported unaudited 2022 interim results ending June 30, 2022,...

Company Drug

Merck’s Gardasil 9-Valent HPV Vaccine Approved for Expanded Age Range in China

Fineline Cube Aug 31, 2022

US-based Merck Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration...

Company Deals

Onekdrug Raises Series B+ Funding to Boost Pharmaceutical B2B Services

Fineline Cube Aug 31, 2022

Hunan Wholesale Pharmaceutical Technology Co., Ltd, operating as Onekdrug, has raised tens of millions of...

Posts pagination

1 … 562 563 564 … 598

Recent updates

  • Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared
  • Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal
  • Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway
  • ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy
  • FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Company Medical Device

Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway

Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.